Forge Therapeutics

About Forge Therapeutics

Forge Therapeutics is a biotechnology company focused on developing novel antibiotics to address the growing issue of antibiotic resistance. The company specializes in targeting bacterial metalloenzymes, which are enzymes that require metal ions to function, to create new classes of antibiotics. This approach aims to combat drug-resistant infections that pose significant risks to common medical procedures such as surgery, chemotherapy, and dialysis. Forge Therapeutics operates in the pharmaceutical and healthcare market, primarily serving healthcare providers, hospitals, and pharmaceutical companies. The business model involves research and development of proprietary antibiotic compounds, securing patents, and entering into collaborations with larger pharmaceutical firms for further development and commercialization. Revenue is generated through milestone payments, licensing fees, and potential royalties from commercialized products. Recently, Forge entered into a collaboration with Roche to develop a novel antibiotic for lung infections, with potential payments totaling $190.5 million.